Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037206
Status:
COMPLETED
Last Update Posted:
2008-10-21
First Post:
2002-05-16
Brief Title:
A Safety Effectiveness Study of Intravenous Anidulafungin With AmBisome for Treatment of Invasive Aspergillosis IA
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome Amphotericin B Liposome for Injection as a Treatment for Invasive Aspergillosis
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of Anidulafungin plus AmBisome may offer an improved outcome for patients treated for Invasive Aspergillosis IA The purpose of this study is to determine the safety and the clinical and microbiological effectiveness of anidulafungin plus AmBisome in treated patients located in the United States Europe and South Africa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A8851001 | None | None | None |